Last reviewed · How we verify

NCT03495245

Identification of Potential Biomarkers for Pain

Status unknown Last updated 19 November 2019
What this trial tests

trial in Fibromyalgia in 200 participants. Status unknown.

Timeline
28 March 2018
Primary endpoint
30 September 2020
30 September 2021

Quick facts

Lead sponsorRowan University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date28 March 2018
Primary completion30 September 2020
Estimated completion30 September 2021
Sites1 location across United States

Conditions studied

Sponsor

Rowan University

Who can join

18 and older, any sex, with Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study investigates the potential of using serum biomarkers to assess pain in fibromyalgia patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Fibromyalgia

Currently open trials in the same condition.

Other Rowan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03495245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing